Receptor Theory
Agonists, Antagonists, Partial & Inverse Agonists
The efficacy spectrum — from 100% activation through silent blockade to constitutive suppression
A receptor reads ligands by both affinity (does it bind?) and efficacy (what does it do once bound?). Agonists activate, antagonists block silently, partial agonists give a ceiling response, and inverse agonists reduce baseline signaling.
- Full agonistIntrinsic activity = 1 (morphine at μ)
- Partial agonistIntrinsic activity 0.2–0.7 (buprenorphine)
- AntagonistIntrinsic activity = 0 (naloxone)
- Inverse agonistIntrinsic activity < 0 (some antihistamines)
- EC50 comparisonFull Emax 100% vs partial 50% maximum
- Competitive antagonistRight-shifts curve, Emax unchanged
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
How ligand classes differ
Imagine a receptor as a switch that can sit in two states: inactive (R) and active (R*). At rest, the equilibrium between these states sets the basal signaling level. A ligand changes the equilibrium by preferentially binding one state.
- Full agonist: binds active state, drives the switch fully to R*. Intrinsic activity = 1.
- Partial agonist: binds both states but only modestly favors R*. Even with every receptor occupied, only a fraction signal.
- Neutral antagonist: binds both states equally; occupies the site but does not shift the equilibrium. Intrinsic activity = 0. Blocks any agonist by physical exclusion.
- Inverse agonist: preferentially binds R, locking the receptor inactive. Signaling falls below baseline if there is constitutive activity to suppress.
Worked example — opioid receptor at the μ site
μ-opioid receptors mediate analgesia, respiratory depression, and euphoria. Compare four ligands at a single μ receptor population:
- Fentanyl (full agonist) — intrinsic activity ≈ 1. At saturating dose, maximum signaling. Respiratory depression risk is severe because there is no ceiling.
- Morphine (full agonist, lower potency) — intrinsic activity ≈ 1, but EC50 is ~50–100× higher. Same maximum, different dose to reach it.
- Buprenorphine (partial agonist) — intrinsic activity ≈ 0.3–0.4. Reaches its own Emax at high occupancy, but that Emax is only ~30–40% of fentanyl's. Respiratory depression has a ceiling — overdose is harder to achieve. Used for opioid use disorder treatment and chronic pain.
- Naloxone (antagonist) — intrinsic activity = 0. Binds with high affinity (Kd in the nanomolar range), displaces any agonist already bound. Used in opioid overdose reversal: a 0.4 mg intramuscular dose can restore breathing within 2–3 minutes.
A single μ receptor, four drugs, four behaviors — all explained by the binding-then-signaling distinction.
Aripiprazole — partial agonism as therapy
Aripiprazole is a D2 dopamine partial agonist used in schizophrenia and bipolar disorder. In brain regions with high dopaminergic tone (mesolimbic, in psychosis), aripiprazole displaces dopamine and produces less signal — functional antagonism, treating positive symptoms. In regions with low tone (prefrontal cortex, possibly tuberoinfundibular pathway), it slightly activates D2 — functional agonism, reducing motor side effects and prolactin elevation compared with pure antagonists. The same drug acts oppositely in different tissues, a feat impossible for a pure agonist or pure antagonist.
Why this spectrum matters clinically
- Overdose safety. Buprenorphine's ceiling effect means a 32 mg dose causes much less respiratory depression than the equivalent morphine.
- Withdrawal management. Methadone (full agonist) saturates receptors and suppresses withdrawal; buprenorphine (partial) does the same with less euphoria risk and a built-in safety ceiling.
- Smoking cessation. Varenicline is a partial α4β2 nicotinic agonist — it relieves craving while blocking the reward of cigarettes that compete for the same site.
- Hormonal pathways. Selective estrogen receptor modulators (tamoxifen, raloxifene) are tissue-selective partial agonists — antagonist in breast but agonist in bone and uterus.
- Beta-blockade. Pindolol has intrinsic sympathomimetic activity (it is a partial beta-1 agonist) — less resting bradycardia than propranolol but also less effect during exercise tachycardia.
- Antidote design. Naloxone, flumazenil (benzodiazepine antagonist), and atipamezole (α2-adrenergic antagonist) all reverse agonist toxicity by competitive displacement.
- Constitutive receptors. Inverse agonists matter for ghrelin, CB1, and 5-HT2C receptors where baseline signaling drives disease.
Common misconceptions
- "A partial agonist is just a weak agonist." No — at full occupancy it still cannot reach the full agonist's Emax. The ceiling is intrinsic to the molecule.
- "Antagonist means it does nothing." An antagonist actively occupies the receptor, blocking endogenous ligands. The "nothing" is no signal, not no binding.
- "Lower EC50 means more efficacious." EC50 is potency. A drug can be very potent with low efficacy (some partials) or low potency with full efficacy.
- "Inverse agonism is rare." Many drugs labeled antagonist for decades — propranolol, ranitidine, several antipsychotics — are technically inverse agonists.
- "Buprenorphine overdose is impossible." The ceiling is for respiratory depression on μ; combined with benzodiazepines or in opioid-naive patients, fatal overdose still occurs.
- "Partial agonists are always preferred." For severe acute pain (e.g., post-op fentanyl), only full agonism reaches the needed analgesia.
| Class | Intrinsic activity | Effect on baseline | Example | EC50 vs full Emax | Use case |
|---|---|---|---|---|---|
| Full agonist | 1.0 | Maximal activation | morphine, fentanyl, albuterol | own EC50, 100% Emax | severe pain, asthma rescue |
| Partial agonist | 0.2–0.7 | Sub-maximal activation | buprenorphine, aripiprazole, varenicline | own EC50, 30–70% Emax | opioid use disorder, schizophrenia, smoking cessation |
| Neutral antagonist | 0 | No change unless agonist present | naloxone, atropine, prazosin | 0% Emax, right-shifts agonist | overdose reversal, blood pressure |
| Inverse agonist | < 0 | Below baseline | several H1 antihistamines, propranolol | negative Emax | allergic rhinitis, HTN |
| Non-competitive antagonist | 0 (irreversible or allosteric) | Reduced Emax | ketamine (NMDA), aspirin (COX) | lowers Emax, insurmountable | dissociative anesthesia, antiplatelet |
| Biased agonist | variable per pathway | Selective activation | oliceridine (μ-opioid biased) | arrestin vs G-protein split | analgesia with less respiratory depression (research) |
Frequently asked questions
What is the difference between affinity and efficacy?
Affinity is how tightly a ligand binds — measured by the equilibrium dissociation constant Kd or by EC50. Efficacy is what the ligand does after binding — measured by intrinsic activity from 0 to 1 (or below). A drug can bind tightly with high affinity but have zero efficacy (a competitive antagonist). Conversely, low-affinity full agonists exist. Modern receptor theory replaces simple efficacy with operational efficacy τ, accounting for receptor reserve.
What is a partial agonist?
A ligand that activates the receptor but cannot reach the maximum response a full agonist produces, even with every receptor occupied. Intrinsic activity is between 0 and 1 — typically 0.2 to 0.7. Buprenorphine is a partial μ-opioid agonist with about 30-40% efficacy compared with morphine; it produces analgesia with a ceiling on respiratory depression, making overdose deaths less common. Partial agonists can act as functional antagonists when a full agonist is already present, because they displace it but produce a smaller signal.
What is an inverse agonist?
Some receptors are constitutively active — they signal at baseline without a ligand. An inverse agonist binds and stabilizes the inactive conformation, suppressing activity below baseline. Many drugs once called antagonists are inverse agonists when tested rigorously — for example, several H1 antihistamines (cetirizine, fexofenadine) are inverse agonists at H1 receptors, and propranolol is a beta-adrenergic inverse agonist. Clinically the distinction matters mostly for receptors with significant constitutive activity, such as cannabinoid CB1 and ghrelin GHSR1a.
Competitive vs non-competitive antagonist?
Competitive antagonists bind the same orthosteric site as the agonist; their effect is surmountable by adding more agonist — the dose-response curve shifts right but the maximum response is unchanged. Naloxone, propranolol, and prazosin are competitive antagonists. Non-competitive antagonists bind a separate site or covalently modify the receptor; they reduce maximal response and cannot be overcome by more agonist. Ketamine is a non-competitive NMDA antagonist; aspirin acetylates COX irreversibly.
How is EC50 measured?
Construct a sigmoidal log-dose vs response curve. EC50 is the concentration producing 50% of the maximum response that drug can elicit (its own ceiling). Note that for a partial agonist, EC50 is half of its own reduced E_max, not half of the full agonist's E_max — comparing potencies between full and partial agonists requires care. The Hill slope describes curve steepness; cooperative binding gives slopes greater than 1, heterogeneous sites give slopes less than 1.
Why does receptor reserve matter?
Many tissues have far more receptors than needed for maximal response — spare receptors. A full agonist hits E_max with only a small fraction of receptors occupied. A partial agonist, occupying nearly all receptors, may still produce only 50% response. Receptor reserve also blunts the effect of competitive antagonists at low doses. Cardiac beta-receptors and intestinal muscarinic receptors have large reserve; this is why beta-blocker titration is gradual and why some drugs paradoxically maintain effect after partial agonism.
Real-world examples of each class?
Full agonists: morphine, fentanyl, albuterol, dopamine, insulin. Partial agonists: buprenorphine (μ-opioid), pindolol (beta-1, with intrinsic sympathomimetic activity), aripiprazole (D2 dopamine — exploits regional partial agonism for antipsychotic effect with less prolactin elevation), varenicline (α4β2 nicotinic, used for smoking cessation). Antagonists: naloxone, propranolol, prazosin, atropine, antihistamines. Inverse agonists: many H1 and H2 antihistamines, atypical antipsychotics, rimonabant (withdrawn CB1 inverse agonist). The classification often depends on the assay system used.